Guardant Health shares slide as colon cancer test is set for FDA advisory committee review
Shares of Guardant Health Inc. (GH) dropped 9.5% premarket on Wednesday after the company said late Tuesday that a U.S. Food and Drug Administration advisory committee will review its colorectal cancer screening test early next year. Guardant earlier this year sought FDA premarket approval for the product, a blood-based test called Shield. Approval was expected in the first quarter of next year, so the scheduling of an advisory committee meeting on March 28 "likely comes as a surprise," Leerink Partners analysts said in a note Tuesday. The timeline for potential approval has been pushed out to the second quarter of next year, the analysts said. "We welcome the opportunity to engage in a discussion with key opinion leaders about our study results and the power of Shield in closing the screening gap once FDA approved," AmirAli Talasaz, co-CEO of Guardant Health, said in a statement. The proposed timing of the meeting is in line with the company's expectation to complete the application process and launch the product in 2024, Talasaz said. Guardant shares have gained 2.6% in the year to date, while the S&P 500 is up 24%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-20-23 0842ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks